PERKINELMER INC Stock Price, News & Analysis

PerkinElmer (NYSE: PKI) is set to present virtually at the J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. The company's CEO, Prahlad Singh, will discuss strategic priorities and provide an update on operations. A live audio webcast will be accessible via the provided link, and a replay will be available on the PerkinElmer Investor Relations website for 30 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 16,000 staff globally, serving customers in 190 countries.

PerkinElmer, a leader in health innovations, has launched the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 for accelerated detection of SARS-CoV-2 variants, including Omicron. The kit enhances sequencing throughput and reduces turnaround time by three hours for 96 samples through advanced normalization beads. It incorporates 1,536 Unique Dual Index barcodes, allowing for the sequencing of 6,000 libraries in a single flow cell, lowering costs. This initiative aims to support SARS-CoV-2 surveillance efforts amid the ongoing pandemic.

PerkinElmer, Inc. (NYSE: PKI) announced that its SARS-CoV-2 RT-PCR assays remain effective despite the emergence of the Omicron variant of concern.

With over 30 reported mutations in the S gene, the company's assays do not target this gene and are unaffected by these changes. In silico assessments indicate no impact on diagnostic accuracy from the Omicron variant.

The company emphasizes the importance of reliable diagnostics amid ongoing concerns regarding transmissibility and vaccine resistance. PerkinElmer's solutions include a comprehensive SARS-CoV-2 portfolio.

PerkinElmer, a global leader in health innovation, will present at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET. Prahlad Singh, the Company’s CEO, will discuss strategic priorities and provide a company update. Interested parties can register for the event here. A webcast will be available on PerkinElmer's Investor website, with a replay accessible for 90 days post-event.

PerkinElmer, a global leader in health innovation, will present at the virtual 2021 Stifel Healthcare Conference on November 16, 2021, at 8:40 a.m. ET. Senior VP and CFO Jamey Mock will discuss the company's strategic priorities. Interested participants can register for the event here. A live audio webcast will be available on the company's Investors page, with a replay accessible for 90 days after.

PerkinElmer reported third quarter 2021 revenue of $1.17 billion, reflecting 21% growth year-over-year, with 12% organic growth. GAAP earnings per share (EPS) from continuing operations fell to $1.11, down from $1.57 in Q3 2020, while adjusted EPS increased to $2.31 from $2.09. The company raised its full-year guidance, forecasting adjusted revenue of $4.9 billion and EPS of $10.81. Key segments, Diagnostics and Discovery & Analytical Solutions, both saw significant revenue increases, contributing to a strong financial outlook.

PerkinElmer, Inc. (NYSE: PKI) has released its 2021 Corporate Social Responsibility (CSR) Report, detailing its progress in environmental, social, and governance (ESG) initiatives. The report highlights a 8.5% reduction in Scope 1 and 2 emissions, a 15% decrease in hazardous waste, and increased female representation in leadership roles to 31%. Four new commitments were announced, targeting carbon neutrality by 2040, waste reduction by 2025, and enhancing female leadership. The company aims to maintain transparency in its ESG goals under SASB guidelines.

The Board of Directors of PerkinElmer (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, set to be paid on February 11, 2022. Shareholders on record by January 21, 2022 will receive this dividend. In 2020, the company reported revenues of approximately $3.8 billion and employs about 15,000 people worldwide. PerkinElmer is a key player in the S&P 500 Index, serving customers in 190 countries, and is focused on innovating for a healthier world.

PerkinElmer (NYSE: PKI) and Honeycomb Biotechnologies have launched the innovative HIVE^TM scRNAseq Solution, designed for single-cell isolation and analysis. This portable device allows the capture, storage, and RNA sequencing of fragile cell types without the need for specialized equipment, enhancing research opportunities. The HIVE solution maintains sample integrity, improving workflow efficiency for multi-site studies. This technology aims to drive advancements in diagnostics and therapeutic development, particularly for academic collaborations and clinical trials.